Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) in the Open-Label, Multi-Center, Global, Single-Arm, Phase Ib/II FELIX Study: The Impact of Bridging Therapies on CAR T-Cell Expansion and Persistence

Jae H. Park, Elias Jabbour, Paul Shaughnessy, Aaron C. Logan, Karamjeet S Sandhu, Mehrdad Abedi, Bijal D Shah, Michael R Bishop, Daniel J. DeAngelo, Pierre Lao-Sirieix, Wolfram Brugger, Martin A Pule, Justin Shang, Claire Roddie

Blood (2024) 144 (Supplement 1): 3458.

https://doi.org/10.1182/blood-2024-201514

Published: 2024

Journal Articles

Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Deep Molecular Remission May Predict Better Outcomes

Elias Jabbour, Jae H. Park, Paul Shaughnessy, Aaron C. Logan, Karamjeet S Sandhu, Mehrdad Abedi, Bijal D Shah, Michael R Bishop, Daniel J. DeAngelo, Pierre Lao-Sirieix, Wolfram Brugger, Martin A Pule, Yiyun Zhang, Claire Roddie

Blood (2024) 144 (Supplement 1): 963.

https://doi.org/10.1182/blood-2024-194508

Published: 2024

Journal Articles

Development of a First-in-Class CAR-T Therapy Against Calreticulin-Mutant Neoplasms and Evaluation in the Relevant Human Tissue Environment

Alexandros Rampotas, Zoe Wong, Isaac Gannon, Camelia Benlabiod, Yuqi Shen, Charlotte Brierley, Aude-Anais Olijnik, Saif Khan, Nawshad Hayder, Gordon Weng-Kit Cheung, Marina Mitsikakou, Manuel Rodriguez-Justo, Abdullah O Khan, Adam J Mead, Jonathan Lambert, Claire Roddie, Bethan Psaila, Martin A Pule

Blood (2024) 144 (Supplement 1): 871.

https://doi.org/10.1182/blood-2024-204953

Published: 2024

Journal Articles

Risk Factors Associated with Sub-Optimal Outcomes Following Obecabtagene autoleucel (obe-cel) for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): What We Have Learned from the FELIX Trial

Claire Roddie, Jae H. Park, Paul Shaughnessy, Aaron C. Logan, Karamjeet S Sandhu, Mehrdad Abedi, Bijal D Shah, Michael R Bishop, Daniel J. DeAngelo, Wolfram Brugger, Martin A Pule, Justin Shang, Elias Jabbour

Blood (2024) 144 (Supplement 1): 4845.

https://doi.org/10.1182/blood-2024-208028

Published: 2024

Journal Articles

Long-Term Efficacy and Safety of Obecabtagene Autoleucel (obe-cel) in Adult Patients (pts) with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia ([R/R B-ALL]; Pooled Analysis from ALLCAR19 and FELIX Phase Ib Studies) or Other B-cell Malignancies (ALLCAR19 Extension Study)

Blood (2023) 142 (Supplement 1): 2114.

https://doi.org/10.1182/blood-2023-180666

Published: 2023

Journal Articles

Development of a Phase 1 Study Evaluating the Activity of Modular CAR T for Multiple Myeloma (MCARTY) Targeting BCMA and CD19 for Improved Persistence

Blood (2023) 142 (Supplement 1): 350.

https://doi.org/10.1182/blood-2023-185085

Published: 2023

Journal Articles

Obecabtagene Autoleucel (obe-cel, AUTO1) for Relapsed/Refractory Adult B-cell Acute Lymphoblastic Leukemia (R/R B-ALL): Pooled Analysis of the Ongoing FELIX Phase Ib/II Study

Blood (2023) 142 (Supplement 1): 222.

https://doi.org/10.1182/blood-2023-179454

Published: 2023

Journal Articles

Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma

Blood (2023) 141 (20): 2470–2482.

https://doi.org/10.1182/blood.2022018598

Published: 2023

Includes: Supplemental data

Journal Articles

Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia

Blood (2022) 140 (1): 25–37.

https://doi.org/10.1182/blood.2021013648

Published: 2022

Includes: Supplemental data

Journal Articles

Anti-CD1a CAR T cells to selectively target T-ALL

Paul M. Maciocia, Martin A. Pule

Blood (2019) 133 (21): 2246–2247.

https://doi.org/10.1182/blood-2019-03-900910

Published: 2019

Journal Articles

A Novel Second Generation CD19 CAR for Therapy of High Risk/Relapsed Paediatric CD19 + Acute Lymphoblastic Leukaemia and Other Haematological Malignancies: Preliminary Results from the Carpall Study

Sara Ghorashian, MD PhD FRCPath, Anne Marijn Kramer, MD, Sarah Jayne Albon, BSc, MSc, Catherine Irving, BSc, Lucas Chan, PhD, Fernanda Castro, PhD, Bilyana Popova, Kim Champion, PhD, Gary Wright, Hong Zhan, PhD, Waseem Qasim, MBBS PhD, Robert Wynn, Rachael Hough, MD BMBS, FRCP, FRCPath, Farzin Farzaneh, Martin A Pule, MD PhD, Persis J Amrolia, Professor

Blood (2016) 128 (22): 4026.

https://doi.org/10.1182/blood.V128.22.4026.4026

Published: 2016

Journal Articles

Construction and Pre-Clinical Evaluation of a New Anti-CD19 Chimeric Antigen Receptor

Anne Marijn Kramer, MD, Sara Ghorashian, MD PhD FRCPath, Gordon Weng-Kit Cheung, MSc, Winston Vetharoy, BVSc, Dale Moulding, PhD, Leila Mekkaoui, MSc, Shimobi Onuoha, PhD, Persis J Amrolia, Professor, Martin A Pule, MD PhD

Blood (2016) 128 (22): 1627.

https://doi.org/10.1182/blood.V128.22.1627.1627

Published: 2016

Journal Articles

Novel Humanised ROR1 Chimeric Antigen Receptors for the Treatment of Haematological Malignancies

Satyen Harish Gohil, MBBS MRCP FRCPath, Marco Della Peruta, PhD, Solange R Paredes-Moscosso, Micaela Harrasser, Gordon Weng-Kit Cheung, MSc, David M Davies, PhD, Martin A Pule, MD PhD, Amit C Nathwani, MD PhD

Blood (2016) 128 (22): 3361.

https://doi.org/10.1182/blood.V128.22.3361.3361

Published: 2016

Journal Articles

An APRIL Based Chimeric Antigen Receptor to Simultaneously Target BCMA and TACI in Multiple Myeloma (MM) Has Potent Activity in Vitro and in Vivo

Lydia Sarah Hui Lee, MBBS, MRCP, MRCPath, BSc, Benjamin Owen Draper, BSc, MSc, Neil Chaplin, BSc, MSc, Brian Philip, PhD, Melody Chin, BSc, MSc, Daria Galas-Filipowicz, BSc, MSc, Simon Thomas, PhD, Evangelia Kokalaki, BSc, MSc, James Francis, PhD, Kwee L Yong, Martin A Pule, MD PhD

Blood (2016) 128 (22): 379.

https://doi.org/10.1182/blood.V128.22.379.379

Published: 2016

Journal Articles

Targeting T-Cell Receptor β-Constant Domain for Immunotherapy of T-Cell Malignancies

Paul Michael Maciocia, BSc,MBBS,MRCP, Patrycja Wawrzyniecka, MSc, Brian Philip, PhD, Ida Ricciardelli, PhD, Ayse U. Akarca, BSc, Shimobi Onuoha, PhD, David Cole, PhD, Andrew Sewell, PhD, Karl S Peggs, MD, David C. Linch, MD MRCP, MB BCh, BA, Teresa Marafioti, MD, Martin A Pule, MD PhD

Blood (2016) 128 (22): 811.

https://doi.org/10.1182/blood.V128.22.811.811

Published: 2016

Journal Articles

Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients

Helen E. Heslop, Karen S. Slobod, Martin A. Pule, Gregory A. Hale, Alexandra Rousseau, Colton A. Smith, Catherine M. Bollard, Hao Liu, Meng-Fen Wu, Richard J. Rochester, Persis J. Amrolia, Julia L. Hurwitz, Malcolm K. Brenner, Cliona M. Rooney

Blood (2010) 115 (5): 925–935.

https://doi.org/10.1182/blood-2009-08-239186

Published: 2010

Includes: Supplemental data

Journal Articles

Multiple Integration Events into Several Putative Oncogenes Was Required To Cause Leukemogenesis in Two Primate Recipients of RCR Contaminated Stem-Cells.

Martin A. Pule, MD, Alexandra Rousseau, MD, Elizabeth Kang, MD, Takahiro Ueda, MD, Christof von Kalle, Arthur W. Nienhuis, MD, Helen Heslop, MD, Elio Vanin, PhD, John F. Tisdale, MD

Blood (2004) 104 (11): 2102.

https://doi.org/10.1182/blood.V104.11.2102.2102

Published: 2004

Journal Articles

Flanking-Sequence Exponential Anchored (FLEA) PCR - a Sensitive and Highly Specific Method for Detecting Retroviral Integrant-Host-Junction Sequences.

Martin A. Pule, MD, Alexandra Rousseau, MD, Elio F. Vanin, PhD, Malcolm K. Brenner, MD, PhD, Helen E. Heslop, MD, PhD

Blood (2004) 104 (11): 2112.

https://doi.org/10.1182/blood.V104.11.2112.2112

Published: 2004

Journal Articles

Inducible Caspase 9 as a Safety Switch in Genetically Modified Cytotoxic T Cells.

Karin C. Straathof, MD, Martin A. Pule, MD, Patricia Yotnda, PhD, Gianpietro Dotti, MD, Elio F. Vanin, PhD, Malcolm K. Brenner, MD, PhD, Helen E. Heslop, MD, PhD, David M. Spencer, PhD, Cliona M. Rooney, PhD

Blood (2004) 104 (11): 1743.

https://doi.org/10.1182/blood.V104.11.1743.1743

Published: 2004

Journal Articles

Three-Module Signaling Endo-Domain Artifical T-Cell Receptor Which Transmits CD28, OX40 and CD3-ζ Signals Enhances IL-2 Release and Proliferative Response in Transduced Primary T-Cells.

Martin A. Pule, MD, Karin C. Straathof, MD, Gianpietro Dotti, MD, Helen E. Heslop, MD, PhD, Cliona M. Rooney, PhD, Malcolm K. Brenner, MD, PhD

Blood (2004) 104 (11): 1747.

https://doi.org/10.1182/blood.V104.11.1747.1747

Published: 2004

NARROW

Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) in the Open-Label, Multi-Center, Global, Single-Arm, Phase Ib/II FELIX Study: The Impact of Bridging Therapies on CAR T-Cell Expansion and Persistence

Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Deep Molecular Remission May Predict Better Outcomes

Development of a First-in-Class CAR-T Therapy Against Calreticulin-Mutant Neoplasms and Evaluation in the Relevant Human Tissue Environment

Risk Factors Associated with Sub-Optimal Outcomes Following Obecabtagene autoleucel (obe-cel) for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): What We Have Learned from the FELIX Trial

Long-Term Efficacy and Safety of Obecabtagene Autoleucel (obe-cel) in Adult Patients (pts) with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia ([R/R B-ALL]; Pooled Analysis from ALLCAR19 and FELIX Phase Ib Studies) or Other B-cell Malignancies (ALLCAR19 Extension Study)

Development of a Phase 1 Study Evaluating the Activity of Modular CAR T for Multiple Myeloma (MCARTY) Targeting BCMA and CD19 for Improved Persistence

Obecabtagene Autoleucel (obe-cel, AUTO1) for Relapsed/Refractory Adult B-cell Acute Lymphoblastic Leukemia (R/R B-ALL): Pooled Analysis of the Ongoing FELIX Phase Ib/II Study

Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma

Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia

Anti-CD1a CAR T cells to selectively target T-ALL

A Novel Second Generation CD19 CAR for Therapy of High Risk/Relapsed Paediatric CD19 + Acute Lymphoblastic Leukaemia and Other Haematological Malignancies: Preliminary Results from the Carpall Study

Construction and Pre-Clinical Evaluation of a New Anti-CD19 Chimeric Antigen Receptor

Novel Humanised ROR1 Chimeric Antigen Receptors for the Treatment of Haematological Malignancies

An APRIL Based Chimeric Antigen Receptor to Simultaneously Target BCMA and TACI in Multiple Myeloma (MM) Has Potent Activity in Vitro and in Vivo

Targeting T-Cell Receptor β-Constant Domain for Immunotherapy of T-Cell Malignancies

Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients

Multiple Integration Events into Several Putative Oncogenes Was Required To Cause Leukemogenesis in Two Primate Recipients of RCR Contaminated Stem-Cells.

Flanking-Sequence Exponential Anchored (FLEA) PCR - a Sensitive and Highly Specific Method for Detecting Retroviral Integrant-Host-Junction Sequences.

Inducible Caspase 9 as a Safety Switch in Genetically Modified Cytotoxic T Cells.

Three-Module Signaling Endo-Domain Artifical T-Cell Receptor Which Transmits CD28, OX40 and CD3-ζ Signals Enhances IL-2 Release and Proliferative Response in Transduced Primary T-Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only